NEW YORK, November 28, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timelyinformation, WallStEquities.com has issued free tailored Stock Review on ONCE, AGEN, CHRS, and ACOR which is a click away at http://www.wallstequities.com/registration. On Monday, November 27, 2017, the NASDAQ Composite
Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc.'s stock finished Monday's session 3.13% lower at $71.79 with a total trading volume of 373,758 shares. The Company's shares have advanced 29.07% over the past twelve months and 43.87% since the start of this year. The stock is trading above its 200-day moving average by 6.45%. Additionally, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have a Relative Strength Index (RSI) of 38.16.
On November 08th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $100 a share to $98 a share. Signing up now gives you access to the free research coverage on ONCE at:
On Monday, shares in Lexington, Massachusetts headquartered Agenus Inc. recorded a trading volume of 662,335 shares. The stock ended the session 1.79% lower at $3.85. The Company's shares have advanced 8.15% in the last month. The stock is trading below its 50-day moving average by 5.92%. Moreover, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have an RSI of 50.65. Get access to our top-rated research, including the free report on AGEN at:
Redwood City, California headquartered Coherus Biosciences Inc.'s shares closed the day 1.71% lower at $8.60. The stock recorded a trading volume of 822,200 shares, which was above its three months average volume of 544.98 thousand shares. The stock is trading below its 50-day moving average by 28.90%. Additionally, shares of Coherus Biosciences, which focuses on developing and commercializing biosimilar products worldwide, have an RSI of 32.42. Click here to subscribe for a free membership which welcomes you with our report on CHRS at:
Shares in Ardsley, New York headquartered Acorda Therapeutics Inc. finished 2.44% lower at $20.00. The stock recorded a trading volume of 657,808 shares. The Company's shares have advanced 6.38% on an YTD basis. The stock is trading below its 50-day moving average by 19.75%. Furthermore, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 37.36.
On November 16th, 2017, research firm Stifel downgraded the Company's stock rating from 'Buy' to 'Hold' while revising its previous target price from $26 a share to $15 a share. Join our big investor community at Wall St. Equities today and start so with your free report on ACOR at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Bladder neck incision is a surgical procedure where cuts are made in the neck of the urinary ...
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...View All